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Influenza A subtype H7 viruses have resulted in >100 
cases of human infection since 2002 in the Netherlands, Italy, 
Canada, the United States, and the United Kingdom. Clinical 
illness from subtype H7 infection ranges from conjunctivitis 
to mild upper respiratory illness to pneumonia. Although sub-
type H7 infections have resulted in a smaller proportion of 
hospitalizations and deaths in humans than those caused by 
subtype H5N1, some subtype H7 strains appear more adapt-
ed for human infection on the basis of their virus-binding 
properties and illness rates among exposed persons. More-
over, increased isolation of subtype H7 influenza viruses from 
poultry and the ability of this subtype to cause severe human 
disease underscore the need for continued surveillance and 
characterization of these viruses. We review the history of 
human infection caused by subtype H7. In addition, we dis-
cuss recently identified molecular correlates of subtype H7 
virus pathogenesis and assess current measures to prevent 
future subtype H7 virus infection.
I
nfluenza A viruses belong to the family Orthomyxoviridae 
and  possess  8  negative-sense  RNA  segments  encoding 
11 known proteins. Of these, the 2 viral surface glycopro-
teins, hemagglutinin (HA) and neuraminidase (NA), form 
the basis of multiple serologically distinct virus subtypes. 
Currently, 16 HA and 9 NA subtypes have been identified 
in wild water birds, the natural host for all influenza A vi-
ruses and the reservoir from which viruses emerge to infect 
domestic  poultry  and  occasionally  mammals.  Most  influ-
enza viruses that infect wild or domestic birds cause no or 
limited illnesses and deaths and are characterized as being 
low pathogenicity avian influenza (LPAI) viruses. However,   
viruses within the H5 and H7 subtypes have the capacity to 
acquire genetic properties that confer high virulence and a 
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Learning Objectives
Upon completion of this activity, participants will be able to:
Describe the transmission mechanism and attack rate for the H7 strain of influenza virus in humans •	
Describe clinical manifestations of H7 virus infection in humans •	
Identify reasons for increased prevalence of human infection with the H7 virus in future •	
Describe differences in clinical presentation of infection with H5N1 and H7 viruses •	
Identify the best strategy for protection against avian virus infection for humans •	
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1. Which of the following best describes the anticipated 
attack rate of a pandemic influenza virus on the basis of 
attack rates in past pandemics?
A.  10% to 15%
B.  25% to 35%
C.  40% to 50%
D.  55% to 65%
2. Which of the following is least likely to be an early clinical 
manifestation of H7 influenza virus?
A.  Pneumonia
B.  Conjunctivitis
C.  Coryza
D.  Encephalitis
3. Which of the following is the most likely reason for 
expectations of future human infection with the H7 avian 
influenza virus?
A.  Increased detection in nonpoultry farm animals
B.  Increased frequency of human and poultry infection
C.  Increased detection of human infection in the  
African continent
D.  All of the above
4. Which of the following best describes the difference 
between infection with H5N1 and H7 subtypes of the avian 
influenza virus in humans?
A.  H5N1 manifests most frequently as neurologic disease
B.  H7 most frequently manifests as conjunctival disease
C.  H7 manifests only rarely as respiratory disease
D.  The 2 infections are indistinguishable clinically
5. Which of the following strategies is considered the best 
protection of humans against avian influenza viruses?
A.  Antiviral agents
B.  Quarantine and slaughter of infected poultry
C.  Vaccination of humans
D.  Handwashing hygiene measures
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3. The content learned from this activity will impact my practice.
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